NKGen Biotech, Inc. Common Stock (NKGN PINK) stock market data APIs
$0.1339
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
NKGen Biotech, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors. The company has a license agreement with NKMAX for its NK cell program. The company has a strategic partnership with HekaBio K.K. for the development of the company's autologous NK cell therapy, troculeucel, in Japan. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Prev. Close
0.1339
Open
0.1339
High
0.1339
Low
0.1339
52 wk Range
0.098-0.9649
Market Cap
13 648 K
Shares Outstanding
103 M
EPS
0.15
Beta
1.181
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NKGen Biotech, Inc. Common Stock data using free add-ons & libraries
Get NKGen Biotech, Inc. Common Stock Fundamental Data
NKGen Biotech, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -30 112 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-04
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NKGen Biotech, Inc. Common Stock News
New
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets
NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approx...
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit
SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerc...
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025
Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration....
FDA grants expanded access for NKGen's cell therapy in neurodegenerative diseases
SANTA ANA, Calif. - The U.S. Food and Drug Administration (FDA) has authorized an Expanded Access Program for NKGen Biotech’s troculeucel, allowing treatment of up to 20 patients with various neurod...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
